

*Name of Committee:* National Institute of Mental Health Initial Review Group; Interventions Committee for Adult Disorders.

*Date:* October 12–13, 2010.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Hyatt Regency Bethesda, One Bethesda Metro Center, 7400 Wisconsin Avenue, Bethesda, MD 20814.

*Contact Person:* David I. Sommers, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, National Institutes of Health, 6001 Executive Blvd., Room 6154, MSC 9606, Bethesda, MD 20892–9606, 301–443–7861, [dsommers@mail.nih.gov](mailto:dsommers@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Initial Review Group; Mental Health Services in MH Specialty Settings.

*Date:* October 15, 2010.

*Time:* 8:30 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* The Dupont Hotel, 1500 New Hampshire Avenue, NW., Washington, DC 20036.

*Contact Person:* Marina Broitman, PhD, Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6153, MSC 9608, Bethesda, MD 20892–9608, 301–402–8152, [mbroitma@mail.nih.gov](mailto:mbroitma@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.242, Mental Health Research Grants; 93.281, Scientist Development Award, Scientist Development Award for Clinicians, and Research Scientist Award; 93.282, Mental Health National Research Service Awards for Research Training, National Institutes of Health, HHS)

Dated: August 25, 2010.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010–21662 Filed 8–30–10; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant

applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Partnerships for Biodefense (Vaccines/Immunotherapeutics 3).

*Date:* September 27, 2010.

*Time:* 11 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Room 3254, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Nancy Lewis Ernst, PhD, Scientific Review Official, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–7383, [nancy.ernst@nih.gov](mailto:nancy.ernst@nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Partnerships for Biodefense (Vaccines/Immunotherapeutics 1).

*Date:* October 8, 2010.

*Time:* 11 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Room 3254, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Nancy Lewis Ernst, PhD, Scientific Review Official, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–7383, [nancy.ernst@nih.gov](mailto:nancy.ernst@nih.gov).

*Name of Committee:* National Institute of Allergy and Infectious Diseases Special Emphasis Panel, Partnerships for Biodefense (Vaccines/Immunotherapeutics 2).

*Date:* October 12, 2010.

*Time:* 11 a.m. to 5 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6700B Rockledge Drive, Room 3254, Bethesda, MD 20892 (Telephone Conference Call).

*Contact Person:* Nancy Lewis Ernst, PhD, Scientific Review Official, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, MSC 7616, Bethesda, MD 20892–7616, 301–451–7383, [nancy.ernst@nih.gov](mailto:nancy.ernst@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: August 25, 2010.

**Jennifer S. Spaeth,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 2010–21647 Filed 8–30–10; 8:45 am]

**BILLING CODE 4140–01–P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Prospective Grant of a Co-Exclusive License: Natural Plant Extracts From Incense Cedar as Pest Control Agents and Methods for Their Use

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This is a notice in accordance with 35 U.S.C. 209(e) and 37 CFR 404.7(a)(1)(i) that the Technology Transfer Office of the Centers for Disease Control and Prevention (CDC), located within the Department of Health and Human Services (HHS), is contemplating the grant of worldwide co-exclusive licenses to practice the inventions embodied in the patents referred to below to Allylix, Incorporated and Valent BioSciences Corporation, having places of business in San Diego, CA and Libertyville, IL, respectively. The patent rights in these inventions have been assigned to the government of the United States of America. The patent(s) to be licensed are:

U.S. Pat. No. 7,629,387, “Compounds for Pest Control and Methods for Their Use,” issued December 8, 2009; and U.S. Pat. No. 7,129,271, “Compounds for Pest Control and Methods for Their Use,” issued October 31, 2006; and all related foreign patent applications. Inventors: Marc C. Dolan, Nicholas A. Panella, Joseph J. Karchesy, Gary O. Maupin. [CDC Tech. ID No. I-024-00]; and U.S. Pat. No. 7,230,033, “Pest Control Compositions and Methods for Their Use,” issued June 12, 2007. Inventors: Marc C. Dolan, Nicholas A. Panella, Gabrielle E. B. Dietrich, Joseph J. Karchesy, Gary O. Maupin [CDC Tech. ID No. I-028-04].

*Additional rights to be licensed are:* “Natural Plant Extracts from Incense Cedar as Pest Control Agents and Methods for Their Use,” submitted February 21, 2008. Inventors: Marc C. Dolan, Nicholas A. Panella, and Joseph J. Karchesy [CDC Tech. ID No. I-019-08].

*Patent Status:* Various.

*Earliest Priority Date:* December 8, 2000.

The prospective co-exclusive licenses will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7.

#### Technology

This technology identifies biologically active fractions of essential oil of Alaska yellow cedar which are insecticidal and acaricidal. These natural compounds were found to be active for up to 11